Endpoints News
Vir strikes deal with Gilead for T cell engagers Read in browser
Endpoints News
Thank you for reading, Test Researcher!
basic
UPGRADE
M T Wed Th F
14 October, 2026
ENDPOINTS at #JPM27 - BIOPHARMA'S NEW BALANCE OF POWER
Biopharma's balance of power is shifting, and in January, Endpoints journalists will press the people at the center of it on who's rising, who's falling and where the industry may land by the end of the decade. Join us at #JPM27 for exclusive conversations and interviews you won't get anywhere else. Save $200 on your all-access pass with Early Bird, or join us virtually for free.
presented by Parexel
Greater em­pa­thy, greater ef­fi­cien­cy: How pa­tient-first clin­i­cal de­vel­op­ment ben­e­fits all of us
top stories
1. Verastem makes its stand as a RevMed competitor in pancreatic cancer
2. Vir makes solid tumor T cell engager deal with Gilead
3.
news briefing
Ultragenyx's second PRV sale; Biomea's oral GLP-1 data leads to stock slump
4. Arrowhead’s brain-targeting drug lowers Alzheimer’s tau protein in early study
5. GSK could cut more than 1,200 jobs in Belgium
6. Zealand inks up to $1.3B deal for AI-designed obesity treatments
more stories
• 
in focus
Karen Weintraub
.

You still have time to catch most of Endpoints’ AI Day, going on virtually now and in person in New York City this afternoon and early evening. Please join us!
.
Karen Weintraub
Deputy Editor, Endpoints News
1
by Lei Lei Wu

Ve­rastem On­col­o­gy had a big Wednes­day morn­ing: it an­nounced new da­ta amid a tense com­pe­ti­tion for the next-wave KRAS agents, as well as a $250...

Read the full story
Marianne De Backer, Vir Biotechnology CEO (Brian Benton Photography)
2
by Lei Lei Wu

Vir Biotech­nol­o­gy and its CEO Mar­i­anne De Backer have notched yet an­oth­er deal, this time with Gilead.

Gilead will pay Vir $65 mil­lion up­front, with an­oth­er...

Read the full story
News Briefing: Quick hits from the biopharma web
3
by ENDPOINTS

Plus news about Unit­ed Ther­a­peu­tics, Liq­uidia, Sanofi, Pharm­ing, Sky­hook Bio and Al­tay Ther­a­peu­tics.

Ul­tragenyx Phar­ma­ceu­ti­cal sells sec­ond PRV this month: The com­mer­cial-stage rare dis­ease drug­mak­er...

Read the full story
4
by Ryan Cross

Ar­row­head Phar­ma­ceu­ti­cals has shown that a ge­net­ic med­i­cine ad­min­is­tered as a sub­cu­ta­neous in­jec­tion can seem­ing­ly trav­el in­to the brain and low­er lev­els of tau, a pro­tein...

Read the full story
5
by Elizabeth Cairns

GSK will make up to 1,217 work­ers re­dun­dant from its sites in Bel­gium as part of the cost-cut­ting ini­tia­tive CEO Luke Miels an­nounced in Ju­ly...

Read the full story
6
by Ayisha Sharma

Zealand Phar­ma said Tues­day it will de­vel­op new pro­tein-based treat­ments for obe­si­ty and oth­er meta­bol­ic dis­eases with the help of Gen­er­ate Bio­med­i­cines’ AI tech­nol­o­gy.

The...